Article
Pharmacology & Pharmacy
Huai-An Chen, Yu-Jen Lu, Banendu Sunder Dash, Yin-Kai Chao, Jyh-Ping Chen
Summary: Combination chemo-photothermal therapy using HA/PMNPc nanoparticles can effectively treat cancer by reducing the dose of chemotherapeutic drugs and inducing cell death through heat generation. The nanoparticles exhibit targeted delivery, pH-sensitive drug release, and hyperthermia effects, resulting in higher cytotoxicity and apoptosis in cancer cells. In vivo studies demonstrate that the treatment modality inhibits tumor growth and increases survival time in mice.
Article
Multidisciplinary Sciences
Mahdie Mousavi, Fereshteh Koosha, Ali Neshastehriz
Summary: A novel nanocomplex, SPIO@AuNP-Cisplatin-Alginate (SACA), was synthesized and characterized. The combination of SACA and 6 MV X-ray significantly decreased the viability of U87MG cells and increased apoptosis, indicating that this nanocomplex effectively enhanced the radiosensitivity of cancer cells.
Article
Oncology
Soo Jin Park, Jaehee Mun, Seungmee Lee, Yanlin Luo, Hyun Hoon Chung, Jae-Weon Kim, Noh Hyun Park, Yong Sang Song, Hee Seung Kim
Summary: LEER showed improved survival outcomes in patients with PSRCC and prior treatment-free interval (PTFI) < 9.2 months, particularly in terms of treatment-free interval, progression-free survival, tumor response, and overall survival. Additionally, LEER significantly reduced the morphine milligram equivalents required for controlling pelvic pain associated with PSRCC when compared to chemotherapy or targeted therapy alone.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Sarah Billingsley, Zsuzsanna Iyizoba, Russell Frood, Sriram Vaidyanathan, Robin Prestwich, Andrew Scarsbrook
Summary: Incomplete imaging response is common after non-surgical treatment for head and neck cancer, and optimal management is uncertain. This study assessed the value of performing a second PET-CT scan in patients with uncertain findings initially after treatment and showed that in most cases, the changes resolved or stayed the same and were not due to residual cancer. This approach could spare unnecessary surgery when there is initial uncertainty.
Article
Oncology
Hui Jiang, Kanjiebubi Makelike, Baoqing Chen, Mian Xi, Qiaoqiao Li, Yonghong Hu, Yujia Zhu
Summary: In this study, we compared the efficacy and toxicity of DP and PF regimens with concurrent chemoradiotherapy (CCRT) in patients with esophageal squamous cell carcinoma (ESCC). The results showed that the DP regimen did not improve the treatment response, overall survival (OS), or progression-free survival (PFS) compared to the PF regimen. The importance of long-term follow-up and salvage treatments was also highlighted. Rating: 7/10.
RADIATION ONCOLOGY
(2023)
Article
Chemistry, Physical
Nan Yang, Tian Zhang, Changyu Cao, Genxiang Mao, Jinjun Shao, Xuejiao Song, Wenjun Wang, Xiaozhou Mou, Xiaochen Dong
Summary: The study effectively combines CDDP with GA-Fe NPs to achieve chemo/chemodynamic synergistic cascade oncotherapy, utilizing H2O2 self-generation, thermal responsiveness, and enhanced CDT effects to effectively kill cancer cells and successfully cure cancer.
Article
Chemistry, Multidisciplinary
Jiazhen Yang, Tianqi Su, Haoyang Zou, Guanqing Yang, Jianxun Ding, Xuesi Chen
Summary: A spatiotemporally targeted nanoantidote was designed to decrease the toxicity of cisplatin without affecting its anticancer efficacy. The nanoantidote selectively accumulated in the liver and kidney and bound to cisplatin, reducing its level in normal organs and increasing tolerance.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
(2022)
Article
Multidisciplinary Sciences
Shengnan Zhou, Tian Tian, Tao Meng, Jin Wu, Danyou Hu, Qiaobo Liao, Jialu Zhuang, Hua Wang, Guiyang Zhang
Summary: This study reports a biomimetic multifunctional COF nanozyme composed of AIEgen-based COF (TPE-s COF) and encapsulated gold nanoparticles (Au NPs). By co-culturing the nanozyme with HepG2 cells, an inactivated form of the TPE-s COF-Au@Cisplatin nanozyme (M@TPE-s COF-Au@Cisplatin) was fabricated, which lost its proliferative ability and pathogenicity. Laser irradiation resulted in the cleavage of M@TPE-s COF-Au@Cisplatin nanozymes, releasing TPE-s COF-Au nanozyme and Cisplatin for photothermal and drug therapeutic effects.
Article
Oncology
Ye Ouyang, Yilin Zhu, Haoyi Chen, Guoquan Li, Xiongwei Hu, Hongyu Luo, Zhou Li, Shuai Han
Summary: Patients with advanced rectal cancer can achieve long-term survival through active multidisciplinary management and R0 surgery.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Timothy A. Ritzmann, Rebecca J. Chapman, John-Paul Kilday, Nicola Thorp, Piergiorgio Modena, Robert A. Dineen, Donald Macarthur, Conor Mallucci, Timothy Jaspan, Kristian W. Pajtler, Marzia Giagnacovo, Thomas S. Jacques, Simon M. L. Paine, David W. Ellison, Eric Bouffet, Richard G. Grundy
Summary: This study reviewed 12 years of data to evaluate treatment strategies and survival rates in children with ependymoma. Patients who underwent gross total resection had the best prognosis, while those with subtotal resection responded well to VEC chemotherapy. Biomarkers associated with poorer survival included 1q gain, H3K27me3 loss, and hTERT expression.
Article
Medicine, General & Internal
Shurei Sugita, Sawako Ogiso, Masanori Fujiwara, Euan Morita, Takuma Koyama, Takahiro Hozumi
Summary: The study aimed to investigate the effects of molecularly targeted therapy after surgical treatment of spinal metastasis. Participants were divided into two groups, one receiving targeted therapy after surgery (TT group) and the other not receiving targeted therapy (non-TT group). The results showed that the TT group had significantly longer median survival, less local recurrence, and better preservation of neurological function and ability to walk compared to the non-TT group. In conclusion, molecularly targeted drugs improve survival but do not alter local control of metastatic tumors in patients with spinal metastasis.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Gastroenterology & Hepatology
Andreas Bogner, Johannes Fritzmann, Benjamin Muessle, Johannes Huber, Jakob Dobroschke, Ulrich Bork, Steffen Wolk, Marius Distler, Juergen Weitz, Thilo Welsch, Christoph Kahlert
Summary: Pelvic exenteration is a high morbidity procedure but the only curative option for advanced or recurrent colorectal and non-colorectal cancer in the pelvis. The study showed differences between colorectal and non-colorectal cancer in terms of survival and postoperative complications. Preoperative neoadjuvant treatment was administered to 65.1% of patients, and R0 resection status significantly correlated with better 2-year survival rates.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
(2021)
Review
Immunology
Run Yang, Changming Tan, Masoud Najafi
Summary: Cardiovascular disorders are a major concern among individuals undergoing cancer therapy, with heart diseases being a common cause of mortality in these patients. Inflammatory changes and fibrosis are key mechanisms of cardiac diseases following chemotherapy and radiotherapy. Chronic oxidative stress, cell death, and overproduction of pro-inflammatory and pro-fibrosis cytokines are the underlying mechanisms of cardiovascular diseases following cancer therapy.
INFLAMMOPHARMACOLOGY
(2022)
Article
Oncology
Cihan Comba, Merve Topaktas, Hilmi Bozkurt, Akif Erbin, Burcu Ozdogan, Omer Demir
Summary: The case presented here is of a 62-year-old woman who underwent total pelvic exenteration for vaginal cancer as a secondary malignancy after radiotherapy for endometrial cancer. The surgery was complicated by the development of an ileo-perineal fistula six months post-operatively.
JOURNAL OF GYNECOLOGIC ONCOLOGY
(2021)
Article
Gastroenterology & Hepatology
Kilian G. M. Brown, Nabila Ansari, Michael J. Solomon, Kirk K. S. Austin, Auerilius E. R. Hamilton, Christopher J. Young
Summary: The early outcomes of six patients who underwent combined pelvic exenteration, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy for advanced or recurrent colorectal cancer with peritoneal metastases suggest that this combined procedure is safe and feasible, but long-term oncological and quality of life outcomes need further investigation.
COLORECTAL DISEASE
(2021)
Review
Endocrinology & Metabolism
Angiolo Gadducci, Nora Lanfredini, Stefania Cosio
GYNECOLOGICAL ENDOCRINOLOGY
(2015)
Review
Oncology
Angiolo Gadducci, Nicoletta Biglia, Roberta Tana, Stefania Cosio, Martina Gallo
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2016)
Review
Oncology
Angiolo Gadducci, Silvestro Carinelli, Giovanni Aletti
GYNECOLOGIC ONCOLOGY
(2017)
Review
Oncology
Angiolo Gadducci, Silvestro Carinelli, Maria Elena Guerrieri, Giovanni Damiano Aletti
GYNECOLOGIC ONCOLOGY
(2018)
Review
Pharmacology & Pharmacy
Angiolo Gadducci, Maria Elena Guerrieri
EXPERT OPINION ON PHARMACOTHERAPY
(2015)
Article
Oncology
Giorgia Mangili, Raffaella Cioffi, Saverio Danese, Luigi Frigerio, Gabriella Ferrandina, Gennaro Cormio, Emanuela Rabaiotti, Giovanna Scarfone, Angiolo Gadducci, Alice Bergamini, Carmela Pisano, Massimo Candiani
GYNECOLOGIC ONCOLOGY
(2018)
Review
Oncology
Angiolo Gadducci, Maria Elena Guerrieri, Stefania Cosio
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2019)
Review
Oncology
Angiolo Gadducci, Maria Elena Guerrieri, Stefania Cosio
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2019)
Review
Oncology
Gadducci Angiolo, Carinelli Silvestro, Guerrieri Maria Elena, Aletti Giovanni Damiano
GYNECOLOGIC ONCOLOGY
(2019)
Article
Oncology
Concetta Laliscia, Angiolo Gadducci, Roberto Mattioni, Francesca Orlandi, Sabina Giusti, Amelia Barcellini, Michela Gabelloni, Riccardo Morganti, Emanuele Neri, Fabiola Paiar
Summary: This study assessed prognostic factors in locally advanced cervical cancer patients treated with cisplatin-based chemoradiotherapy using MRI data. Factors such as age, FIGO stage, and certain radiomic features were found to be significant in predicting patient outcomes. The combination of clinical and radiomics features can help in making more accurate treatment decisions for LACC patients.
Review
Oncology
Angiolo Gadducci, Stefania Cosio
Summary: Patients with metastatic or recurrent endometrial cancer who are not suitable for surgery and/or radiotherapy often have unsatisfactory clinical outcomes with pharmacological treatment. The combination of carboplatin + paclitaxel is the standard first-line chemotherapy, while hormonal therapy is sometimes used for steroid receptor-positive EC patients. Immune checkpoint inhibitors, such as pembrolizumab and dostarlimab, have shown good objective responses in highly pretreated patients with MMR-deficient EC.
Article
Medicine, General & Internal
Marina Fabbi, Delfina Costa, Daniela Russo, Laura Arenare, Gabriele Gaggero, Simona Signoriello, Giovanni Scambia, Carmela Pisano, Nicoletta Colombo, Nunzia Simona Losito, Gilberto Filaci, Anna Spina, Daniela Califano, Giosue Scognamiglio, Angiolo Gadducci, Delia Mezzanzanica, Marina Bagnoli, Silvano Ferrini, Vincenzo Canzonieri, Paolo Chiodini, Francesco Perrone, Sandro Pignata
Summary: By investigating the expression of ADAM17 in ovarian cancer tissues, this study aimed to identify prognostic factors for advanced ovarian cancer patients undergoing first-line therapy. The results showed that high expression of ADAM17 was associated with worse prognosis, especially in patients with no residual disease at baseline.
Review
Oncology
Angiolo Gadducci, Giovanni D. Aletti, Fabio Landoni, Roberta Lazzari, Giorgia Mangili, Paola Olivas, Sandro Pignata, Vanda Salutari, Enrico Sartori, Giovanni Scambia, Gian Franco Zannoni, Roberto Sabbatini, Domenica Lorusso
Summary: This article summarizes evidence-based guidelines developed by the Italian Medical Oncology Association for the management of ovarian cancer patients. The guidelines cover surgical, chemotherapy, and molecularly targeted agents for early, advanced, and recurrent disease. Levels of evidence and strength of recommendation are reported for each issue.
Article
Oncology
T. Maggino, P. Zola, E. Sartori, L. Fuso, C. Papadakis, A. Gadducci, F. Landoni
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY
(2015)
Article
Oncology
Angiolo Gadducci, Alice Menichetti, Ilaria Guiggi, Margherita Notarnicola, Stefania Cosio
ANTICANCER RESEARCH
(2015)